US biomedical company Femasys Inc. (NASDAQ: FEMY) announced on Thursday a partnership with Kebomed Europe AG, a European distributor of medical devices, to commercialise FemBloc Permanent Birth Control in France and the Benelux region.

France has been identified as the largest single-market opportunity for FemBloc in Europe, making the collaboration a pivotal step in Femasys' regional growth strategy following its recent CE mark approval.

FemBloc is the only non-surgical permanent birth control option currently available, addressing an unmet need in women's reproductive health. It employs a patented delivery system that places a blended polymer into the fallopian tubes, creating natural scar tissue for permanent occlusion. Unlike surgical sterilisation, it has been designed to eliminate the risks of anaesthesia, infection, and recovery downtime, offering a safer, more accessible, and cost-effective solution.

With no direct alternatives on the market, FemBloc represents broad international potential.